Pricing & Access· May 31, 2026 · 13 min read
Retina buy-and-bill inventory risk when payer preference changes
By Ran Chen#Anti-VEGF#Ophthalmology#Buy and Bill
Topic
Anti-VEGF
Vascular endothelial growth factor inhibitors, aflibercept, ranibizumab, bevacizumab, and ophthalmic biosimilar competition.
Pricing & Access· May 27, 2026 · 13 min read
Eylea HD vs Vabysmo access comparison for retina practices
Biosimilars· May 27, 2026 · 9 min read
Lucentis biosimilars access guide for retina practices
By Ran Chen#Biosimilars#Anti-VEGF#Ophthalmology
Pricing & Access· May 27, 2026 · 10 min read
Vabysmo coverage guide for retina access
Biosimilars· May 21, 2026 · 8 min read